J. Shipley

发表

A First‐in‐Patient, Multicenter, Double‐Blind, 2‐Arm, Placebo‐Controlled, Randomized Safety and Tolerability Study of a Novel Oral Drug Candidate, CTP‐499, in Chronic Kidney Disease

J. Neutel, Lijun Wu, L. Sabounjian, 2016, Clinical pharmacology in drug development.

A Randomized Phase I Evaluation of CTP‐499, a Novel Deuterium‐Containing Drug Candidate for Diabetic Nephropathy

M. Harnett, L. Sabounjian, V. Braman, 2013, Clinical pharmacology in drug development.

Design and Rationale for Randomized, Doubleblind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Patients With Diabetic Nephropathy (DN)

Lijun Wu, M. Harnett, L. Sabounjian, 2012 .

Pharmacokinetics of Once‐Daily Trospium Chloride 60 mg Extended Release and Twice‐Daily Trospium Chloride 20 mg in Healthy Adults

N. Silver, M. Harnett, L. Sabounjian, 2010, Journal of clinical pharmacology.

Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone.

L. Verhey, A. Zietman, M. Goitein, 1995, International journal of radiation oncology, biology, physics.

Study of the Population Pharmacokinetic Characteristics of Once-Daily Trospium Chloride 60 mg Extended-Release Capsules in Patients with Overactive Bladder and in Healthy Subjects

M. Harnett, L. Maclean, U. Schwiderski, 2013, Clinical Drug Investigation.

The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix

C. Pratt, M. Garnick, M. Campion, 2004 .

Radiation therapy for localized prostate carcinoma: experience at the Massachusetts General Hospital (1973-1981).

W. Shipley, A. Althausen, G. Prout, 1988, NCI monographs : a publication of the National Cancer Institute.

Flow cytometric analysis of DNA ploidy, percent S-phase fraction, and total proliferative fraction as prognostic indicators of local control and survival following radiation therapy for prostate carcinoma.

A. Zietman, R. Colvin, W. Shipley, 1994, International journal of radiation oncology, biology, physics.

Predictive Power of an In Vitro System to Assess Drug Interactions of an Antimuscarinic Medication: A Comparison of In Vitro and In Vivo Drug‐Drug Interaction Studies of Trospium Chloride With Digoxin

A. Profy, K. Lasseter, M. Harnett, 2006, Journal of clinical pharmacology.

217 Increase in the electrocardiographic QTC interval in men with prostate cancer undergoing androgen deprivation therapy: Results of three randomized controlled clinical studies

C. Pratt, M. Garnick, M. Campion, 2004 .

The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix.

C. Pratt, M. Garnick, M. Campion, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcome for men with prostate cancer treated with radiation as solo therapy

A. Zietman, W. Shipley, A. Althausen, 1994 .